Vivos (RDGL) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vivos 5-Year Yield-on-Cost %?

Vivos RDGL -3.38% 5-Year Yield-on-Cost % is 0.00 as of Aug. 03, 2026. The stock has 4 warning signs investors should review. Among 318 Medical Devices & Instruments companies, Vivos ranks worse than 314465.09% on this metric.

Vivos's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Vivos's 5-Year Yield-on-Cost % or its related term are showing as below:



RDGL's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.435
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Vivos  (OTCPK:RDGL) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Vivos 5-Year Yield-on-Cost % Related Terms


RDGL vs ARAY, FOFA, TELA: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, Vivos's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Vivos's 5-Year Yield-on-Cost % falls into.



Vivos 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Vivos is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Vivos (RDGL) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vivos and its competitors. According to the industry distribution chart, Vivos ranks #999999 out of 318 companies in the Medical Devices & Instruments industry.
Is Vivos' 5-Year Yield-on-Cost % too high?
Vivos' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Vivos ranks #999999 out of 318 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Vivos' 5-Year Yield-on-Cost % compare to ARAY and FOFA?
According to the Medical Devices & Instruments industry distribution chart, Vivos ranks #999999 out of 318 companies for 5-Year Yield-on-Cost %. This places Vivos in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.44, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vivos and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos stock overvalued right now?
Vivos (RDGL) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Vivos (RDGL), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivos Business Description

Address 1030 N Center Parkway, Kennewick, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.